Is there neuroprotection in Parkinson syndrome?
Parkinson's disease (PD) is a neurodegenerative disorder of the aging population with unknown etiopathogenesis. It is assumed that the underlying pathobiochemical processes comprise multifactorial and multigenetic disturbances leading to a progressive and devastating disorder without remission. Subtypes exist suggesting that "PD" is a spectrum disorder with variations in the cascade of pathobiochemical and genetic events. Neuroprotective endogenous processes are lost at the very beginning of PD. Supplementation of substances with neuroprotective and/or neurorescue capacity is eminent for future therapeutic strategies. MAO-B inhibitors, NMDA-receptor antagonists and dopamine receptor agonists fulfill such a criterion in preclinical studies while there is no clear evidence for clinical neuroprotection. However, PET-controlled studies comparing L-DOPA-treated and ropinirol-treated PD patients give evidence for the "concept of neuroprotective treatment strategies".
Riederer
P
P
Clinic and Policlinic of Psychiatry and Psychotherapy, University of Würzburg, Germany.
Sian
J
J
Gerlach
M
M
D018491:Dopamine Agonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012642:Selegiline / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use
D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D014810:Vitamin E; D012642:Selegiline